Drug industry proposes limits on advertising

Facing a reaction against consumer drug advertising, the pharmaceutical industry moved toward self-policing yesterday by releasing draft guidelines that endorse a period of informing doctors about new drugs before running ads for them. The guidelines, whose final wording is still being worked out, try to address growing pressure from a variety of fronts, including Capitol Hill and the American Medical Association, and even from within the industry itself. They may not satisfy consumer groups, however, who called the guidelines a gesture to placate Congress.

- read this story from The New York Times for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.